Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2012

View Archived Issues

Xention identifies novel ion channel blockers for atrial fibrillation

Seachaid Pharmaceuticals compounds active against Gram-positive bacteria

Opaxio receives FDA orphan drug designation

Coyote Pharmaceuticals plans clinical program with CNS-102

Encouraging phase III results for rFIXFc in hemophilia B

Pfizer discloses new antibacterial agents

Novel TRPM8 channel antagonists presented by Pfizer

PAC-14028 evaluated as a treatment for pruritus

The Vanderbilt University patents new mGlu5 receptor allosteric modulators

Czech scientists report novel dual PGE2 and NO production inhibitors

NuCana BioMed synthesizes new thymidylate synthase inhibitors

Phase IIb study of NBI-98854 in tardive dyskinesia commences

Eliglustat tartrate meets primary endpoint in phase III trial in Gaucher's disease

FDA panel recommends approval of Argus II Retinal Prosthesis System

Acacia Pharma reports results from phase IIa APD-403 study

IND cleared for Omeros' lead PDE10 candidate

NIAID grant awarded to AvidBiotics for antibacterial proteins

Diacomit approved in Japan for Dravet syndrome

Japanese approval granted for Buphenyl for urea cycle disorders

Delamanid can be administered with efavirenz

GTx sells Fareston

SBIR grant supports Colby Pharmaceutical's work in prostate cancer

ArQule and Daiichi Sankyo discontinue phase III MARQUEE trial

NDA submitted for vortioxetine for major depressive disorder

Janssen licenses rights to Astellas' oral JAK inhibitor

U.S. government awards GeoVax a grant for its HIV vaccine program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...